SAN DIEGO, July 6, 2026
Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating tinlarebant (LBS-008) for Stargardt disease (STGD1) will be presented during two major international ophthalmology conferences in July 2026. The presentations will take place at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) in Sydney, Australia, and the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montréal, Canada. The company will highlight topline findings from the pivotal Phase 3 DRAGON study, which previously met its primary endpoint, further supporting the development of tinlarebant as a potential treatment for Stargardt disease, an inherited retinal disorder with no approved therapies.
Phase 3 DRAGON Trial Results to Be Presented by International Retina Experts
At the ISCEV Annual Symposium, Professor John Grigg, M.D., Professor of Clinical and Experimental Ophthalmology and Co-Director of the Save Sight Institute at the University of Sydney, will present the topline results from the Phase 3 DRAGON study on July 8, 2026. A second oral presentation will be delivered by Paul Bernstein, M.D., Ph.D., Professor of Ophthalmology and Visual Sciences at the Moran Eye Center, University of Utah, during the ASRS Annual Meeting on July 18, 2026. Both sessions will discuss the clinical findings from the pivotal study evaluating tinlarebant in adolescent patients with Stargardt disease and its potential impact on future treatment strategies for inherited retinal disorders.
Tinlarebant Targets the Underlying Cause of Stargardt Disease
Tinlarebant is an investigational oral therapy designed to reduce the accumulation of toxic vitamin A-derived bisretinoids, which contribute to retinal degeneration in Stargardt disease and geographic atrophy associated with advanced dry age-related macular degeneration (AMD). The therapy works by lowering circulating levels of retinol-binding protein 4 (RBP4), limiting the transport of vitamin A to the retina and reducing the formation of toxic retinal byproducts. Tinlarebant has received multiple regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in several regions, reflecting its potential to address a significant unmet medical need.
Advertisement
Belite Bio Continues Expanding Its Retinal Disease Clinical Program
Stargardt disease is the most common inherited macular dystrophy affecting both children and adults and is caused by mutations in the ABCA4 gene, leading to progressive central vision loss. Following the successful completion of the Phase 3 DRAGON study, Belite Bio is continuing development of tinlarebant through the ongoing Phase 2/3 DRAGON II trial in Stargardt disease and the Phase 3 PHOENIX study evaluating the therapy in patients with geographic atrophy secondary to advanced dry age-related macular degeneration. The upcoming presentations reinforce Belite Bio’s commitment to advancing innovative therapies for inherited retinal diseases and expanding the clinical evidence supporting tinlarebant.
Source: Belite Bio press release
